HSBC Put 3200 TDXP 18.12.2024/ DE000HS14708 /
2024-11-13 10:14:29 AM | Chg.+0.020 | Bid10:00:36 PM | Ask10:00:36 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.230EUR | +9.52% | - Bid Size: - |
- Ask Size: - |
TECDAX | 3,200.00 EUR | 2024-12-18 | Put |
GlobeNewswire
07-22
MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire
2018-06-12
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
2016-12-13
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
2016-12-06
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
2016-12-06
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
2016-11-28
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
2016-11-17
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
2016-11-15
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
2016-11-08
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
2016-11-03
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
2016-11-02
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
2016-10-20
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire
2016-10-17
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire
2016-10-01
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire
2016-10-01
Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire
2016-09-29
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis